News

The committee has informed the company that the cumulative safety data generated thus far from the Emerald and Pearl Phase III trials support continuation of the studies. In

The new trial will employ two immunotherapeutic vaccines designed to work in concert to activate the immune system to recognize and kill tumor cells in breast and ovarian

The study demonstrated that Chrysalin extensively decreases myocardial injury when administered following a major ischemic insult. Endpoints of the study included infarct size, coronary microvessel function, myocardial function

The drug candidate was studied by Odyssey Thera as part of the ongoing collaboration with Pfizer. The achievement of this milestone is said to be the company’s first

Upon completion of the arrangement, Calyx will be the holder of all of the assets, property and undertaking of Chromos, together with additional cash of $2.35 million (before

The FDA has accepted SuperGen’s application upon review of data from in vitro studies in glioblastoma cell lines that demonstrate that either MP-470 or ionizing radiation alone induce

BioSante will immediately assume all manufacturing, distribution and marketing responsibilities for Elestrin. Elestrin is a fast-drying gel formulation of estradiol, the same estrogen produced naturally in women, and

Lava had been in negotiations with Health Enhancement Products (HEPI) a few years ago but could not proceed as HEPI did not have the clinical results for ProAlgaZyme

Initial studies suggest that Exebryl-1 may have an important dual capacity by inhibiting and reducing tau protein from forming paired helical filaments, important in neurofibrillary tangle formation. The